Novo Nordisk A/S needs to be ready to take calculated risks on deals in order to win, Chief Executive Officer Mike Doustdar said, sketching out the Ozempic maker’s strategy as it seeks to regain lost ground in the increasingly competitive obesity market.
Novo CEO Says Risk-Taking, Deals Are Needed to Win Obesity Race